Company profile / NATHBIOGENES

Nath Bio-Genes

Other · 1 quarter tracked · source-linked performance and management context.

Research layer active
PositiveDelivery assessment incompleteLatest record q4-fy26

Latest revenue

₹51.59 Cr

verified financial record

Quarters tracked

1

source records in the directory

Delivery assessment

Unscored

No scored management commitments are present yet.

Call date

2026-05-15

latest available source date

Signal trajectory

1 actual quarter
PAT (₹ Cr)PositiveWatchNegative
1 actual records
Actual quarterly PAT (₹ Cr) trajectoryReported values plotted by quarter. Hover or focus a point for its quarter, value, and source sentiment.Q4 FY26: -0 · Positive source sentiment · 2026-05-15Q4 FY26-0-0
Values are taken from the available verified source records; sentiment color is a separate source-read indicator.

Current read

Unscored

No scored management commitments are present yet.

Latest source read

What changed this quarter?

Open quarter read

Nath Bio-Genes delivered a strong FY26 with revenue of ₹431.6 crore, up 19% YoY, driven by robust volume growth across cotton (+22%), paddy (+25%), and maize (+54%). EBITDA margin stood at 12%, while PAT declined 8% to ₹38.4 crore due to higher finance costs and tax rate normalization. The company highlighted production stability for flagship cotton hybrids Sankit and Jumbo, and a landmark ₹15 crore contribution from the Uzbekistan JV. Management guided for 15-20% revenue growth in FY27 with stable margins, despite potential El Niño risks. Key risks include inventory buildup (₹113 crore) and gross margin normalization from 63% to 56%.

Colored figures compare against the previous available record. Hover or focus one for the comparison.

Signal

Positive

Revenue

₹51.59 Cr

Source date

2026-05-15

Across the record

Quarter history.

1 source records

History modules

Follow the numbers and themes.

Revenue history PAT history Margin trend Guidance tracker Bear-case history Language trends FY26 summary